Return to site
Return to site

RemeGen's ADC Cancer Drug Granted Conditional Marketing Approval in China

broken image

June 9, 2021 -- RemeGen Co., Ltd. (RemeGen, 9995.HK) announces that disitamab vedotin (RC48, Brand Name: 爱地希®), the novel anti-HER2 antibody-drug conjugate (ADC) independently developed in-house by the Company, has been granted conditional marketing approval by the National Medical Products Administration of the People’s Republic of China for the treatment of locally advanced or metastatic gastric cancer (gastroesophageal junction (GEJ) carcinoma) (GC).

Disitamab vedotin (RC48, Brand Name: 爱地希®) is the second approved marketing  product following the approval granted for telitacicept in March this year in China and is also a significant accomplishment of RemeGen. It signifies the Company’s achievements in the field of oncology. It also demonstrates RemeGen’s ability to develop biologic drugs and reflects the Company’s strong inhouse research and development capabilities, especially the ability to develop ADC products.

ABOUT DISITAMAB VEDOTIN (RC48, Brand Name: 爱地希®)

Disitamab vedotin (RC48, Brand Name: 爱地希®) is an anti-HER2 antibody drug conjugate targeting prevalent cancers with significant unmet medical needs, and it is the first domestically developed ADC in China to have entered clinical development. We are implementing a differentiated development and commercial strategy for disitamab vedotin, targeting prevalent HER2 expressing indications that are currently underserved, including HER2 expressing and HER2 low-expressing breast cancer (BC), HER2 expressing gastric cancer (GC) and urothelial carcinoma (UC), and other HER2 expressing cancer indications. These therapeutic areas represent a less crowded and underserved field for HER2 targeted therapies, and a broad addressable patient population for disitamab vedotin.

Source: RemeGen

Related News:

RemeGen's Telitacicept Granted Conditional Marketing Approval to Treat Systemic Lupus Erythematosus (SLE) in China (2021/03/11)

RemeGen Debuts on Hong Kong Stock Exchange (2020/11/09)

RemeGen Completes USD $100 Million Plus in Funding (2020/04/02)

Previous
NiKang Therapeutics Announces Completion of $200 Million...
Next
Synthekine Announces $107.5 Million Oversubscribed Series...
 Return to site
Cookie Use
We use cookies to improve browsing experience, security, and data collection. By accepting, you agree to the use of cookies for advertising and analytics. You can change your cookie settings at any time. Learn More
Accept all
Settings
Decline All
Cookie Settings
Necessary Cookies
These cookies enable core functionality such as security, network management, and accessibility. These cookies can’t be switched off.
Analytics Cookies
These cookies help us better understand how visitors interact with our website and help us discover errors.
Preferences Cookies
These cookies allow the website to remember choices you've made to provide enhanced functionality and personalization.
Save